医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Topcon Introduces NW500 Non-Mydriatic Retinal Camera

2022年10月06日 AM11:00
このエントリーをはてなブックマークに追加


 

TOKYO

Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, is pleased to announce that it has launched the NW500, its new fully-automatic, non-mydriatic retinal camera that delivers reliable, sharp-quality imaging with enhanced capability.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005153/en/

The new NW500 fully automated non-mydriatic retinal camera from Topcon. (Photo: Business Wire)

The new NW500 fully automated non-mydriatic retinal camera from Topcon. (Photo: Business Wire)

The NW500 offers innovative slit scan illumination and a rolling shutter mechanism, which helps to overcome one of the known causes of poorly graded images in its ability to effectively image smaller pupils, from 2.00mm or more*. A 12-megapixel sensor delivers excellent quality colour fundus images for clear review and analysis.

The NW500 contributes to a streamlined workflow and enhanced patient experience by offering the ability to acquire retinal images in a lighted setting without the need to dilate patients. The NW500 offers excellent quality colour fundus images across the traditional 3 fixation points (Disc, Centre, and Macula), as well as the 9 fixation positions for peripheral photography.

Touch-screen operation offers rapid, simple capture with just one touch. Fully-automated operation gives clinicians the flexibility to delegate screening to non-clinical staff. The improved processing speed** means it takes less time to capture images and gives operators the ability to increase patient throughput.

A variety of connectivity options are available to suit the needs of clinical and screening businesses.

“The NW500 reflects Topcon’s commitment to continuous innovation in pursuit of technology that helps to improve the quality-of-care patients receive and make care more efficient and accessible,” says Senior Director of Product Management, Tobias Kurzke. “Combined, the innovative slit scan technology and 12-megapixel camera offer clinicians fast, sharp quality imaging with less failure and retakes, making the process of acquiring fundus images faster and more reliable than before. The added benefit of enhancing the patient experience through faster screening times and the absence of the need for dilation will give clinicians and large volume wellness screening settings a competitive advantage.”

For more information, visit https://topconhealthcare.jp/products/nw500

About Topcon Healthcare
Topcon Healthcare sees eye health differently. Our vision is to empower providers with smart and efficient technologies for enhanced patient care. Keeping pace with the ever-changing landscape of the healthcare industry, we offer the latest integrated solutions including advanced multi-modal imaging, vendor-neutral data management, safe distancing, and ground-breaking remote diagnostic technology.

A globally-oriented business, Topcon is focused on developing solutions towards solving societal challenges in the mega-domains of healthcare, agriculture, and infrastructure. In healthcare, these challenges include increasing eye disease, rising medical costs, access to healthcare and physician shortages. By investing in value-driven innovations, Topcon works to enable people to enjoy good health and a high quality of life.

* Confirmed on model eye
** As compared to the Topcon non-mydriatic retinal camera TRC-NW400

Not all products, services or offers are approved or offered in every market, and products vary from one country to another. Contact your local distributor for country-specific information and availability.

https://topconhealthcare.jp/

View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005153/en/

CONTACT

Topcon Corporation Eyecare Business Division

Yasuko Sasaki

infomid@topcon.co.jp

同じカテゴリーの記事 

  • EverEx Secures iF Design Award for “MORA,” a Leading Musculoskeletal Rehabilitation Solution
  • Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
  • SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
  • Oriola Partners With HCLTech to Enhance Customer Experience Through Digital Transformation
  • Takeda将在近期召开的股东大会上公布董事会候选人名单